<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02224066</url>
  </required_header>
  <id_info>
    <org_study_id>MEIX-VALV-002</org_study_id>
    <secondary_id>REAC TAVI</secondary_id>
    <nct_id>NCT02224066</nct_id>
  </id_info>
  <brief_title>Platelet Reactivity After TAVI: A Multicenter Pilot Study</brief_title>
  <acronym>REAC-TAVI</acronym>
  <official_title>Assessment of Platelet REACtivity After Transcatheter Aortic Valve Implantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andres Iñiguez Romo, MD, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Spanish Society of Cardiology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital de Meixoeiro</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A high platelet reactivity in patients with severe symptomatic Aortic Stenosis (AS) selected
      for TAVI (Transcatheter aortic valve implantation) procedure has been demonstrated
      previously, and the use of double antiaggregation therapy (DAPT) with Clopidogrel and
      Acetylsalicylic acid (ASA) do not achieve consistent and adequate suppression of platelet
      reactivity. The purpose of this study is evaluate the efficacy of ticagrelor alone versus
      DAPT with clopidogrel and aspirin for the suppression of high platelet reactivity following
      TAVI.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the effectiveness of ticagrelor compared to clopidogrel and aspirin for the suppression of residual platelet reactivity by a system to verify the patient's platelet reactivity (VerifyNow P2Y12 assay).</measure>
    <time_frame>Three months after antiplatelet treatment initiation following procedure.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effectiveness of ticagrelor compared to clopidogrel and aspirin for the suppression of residual platelet reactivity by VerifyNow P2Y12 assay.</measure>
    <time_frame>Six hours after antiplatelet treatment initiation following procedure.</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Assess the safety of antiplatelet monotherapy with ticagrelor compared to DAPT with aspirin and clopidogrel, with regard to the incidence of investigator-reported clinical events according to predefined criteria, including bleeding definitions.</measure>
    <time_frame>Three months after antiplatelet treatment initiation following procedure.</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Severe Aortic Valve Stenosis</condition>
  <condition>Transcatheter Aortic Valve Implantation</condition>
  <condition>Transcatheter Aortic Valve Replacement</condition>
  <arm_group>
    <arm_group_label>Ticagrelor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with high-on-treatment platelet reactivity (PRU ≥ 208)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin/Clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with high-on-treatment platelet reactivity (PRU ≥ 208)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Registry arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients with normal-on-treatment platelet reactivity (PRU &lt; 208) will continue with Aspirin 100 mg plus Clopidogrel 75 mg daily during three months following TAVI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor 90 mg twice per day during three months following TAVI</intervention_name>
    <arm_group_label>Ticagrelor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin 100 mg plus Clopidogrel 75 mg daily during three months following TAVI</intervention_name>
    <arm_group_label>Aspirin/Clopidogrel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        For inclusion in the study subjects should fulfill the following criteria:

          1. Provision of informed consent prior to any study specific procedures.

          2. Adult patients (more than 18 years) with ability to understand and accept the
             participation in the clinical trial.

          3. Patients with degenerative symptomatic severe AS accepted for TAVI after evaluation of
             the Heart Team of each center.

          4. Patients who are not participating in any other clinical trial or research study
             (registries allowed).

        Exclusion Criteria:

        Subjects should not enter the study if any of the following exclusion criteria are
        fulfilled:

          1. Recent stroke &lt;14 days prior to TAVI, non-revascularized severe coronary or carotid
             artery disease (&gt;70% stenosis) or life expectancy &lt; 12 months

          2. Patients under chronic oral anticoagulation

          3. Patients with proven allergy to aspirin, clopidogrel or ticagrelor

          4. Patients that after TAVI cannot undergo a regimen of single or dual antiplatelet
             therapy for 3 months due to a new post-TAVI medical indication

          5. Known pregnancy or breast-feeding

          6. Concomitant oral or intravenous therapy with potent inhibitors of cytochrome P450 3A
             (CYP3A) that cannot be suspended during the course of the study. Medications
             considered as potent inhibitors are: ketoconazole, itraconazole, voriconazole,
             telithromycin, clarithromycin (or erythromycin but not astromicin, nefazodone,
             ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, and more than a daily liter
             of grapefruit juice.

          7. Thrombocytopenia (&lt;50,000 platelets U/L) well documented and clinically relevant.

          8. Patients with documented moderate or severe hepatic insufficiency

          9. Any condition that may put the patient at risk or influence the outcome of the trial

         10. Patients previously randomized in this trial or in another clinical trial with an
             investigational product or device over the past 30 days.

         11. Patients who cannot attend follow up visits scheduled in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrés Iñiguez Romo, MD;Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xerencia de Xestión Integrada de Vigo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Victor A Jimenez Diaz, MD; Msc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xerencia de Xestión Integrada de Vigo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pablo Juan Salvadores, Pharma; MPH</last_name>
    <role>Study Director</role>
    <affiliation>Xerencia xestión integrada de Vigo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clinic Universitari Bellvitge</name>
      <address>
        <city>L' Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Álvaro Cunqueiro</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36312</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Creu i Sant Creu</name>
      <address>
        <city>Barcelona</city>
        <zip>08026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Arrixaca</name>
      <address>
        <city>Murcia</city>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Brown DL, Block PC, Guyton RA, Pichard AD, Bavaria JE, Herrmann HC, Douglas PS, Petersen JL, Akin JJ, Anderson WN, Wang D, Pocock S; PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010 Oct 21;363(17):1597-607. doi: 10.1056/NEJMoa1008232. Epub 2010 Sep 22.</citation>
    <PMID>20961243</PMID>
  </reference>
  <reference>
    <citation>Ussia GP, Scarabelli M, Mulè M, Barbanti M, Sarkar K, Cammalleri V, Immè S, Aruta P, Pistritto AM, Gulino S, Deste W, Capodanno D, Tamburino C. Dual antiplatelet therapy versus aspirin alone in patients undergoing transcatheter aortic valve implantation. Am J Cardiol. 2011 Dec 15;108(12):1772-6. doi: 10.1016/j.amjcard.2011.07.049. Epub 2011 Sep 10.</citation>
    <PMID>21907949</PMID>
  </reference>
  <reference>
    <citation>Makkar RR, Fontana GP, Jilaihawi H, Kapadia S, Pichard AD, Douglas PS, Thourani VH, Babaliaros VC, Webb JG, Herrmann HC, Bavaria JE, Kodali S, Brown DL, Bowers B, Dewey TM, Svensson LG, Tuzcu M, Moses JW, Williams MR, Siegel RJ, Akin JJ, Anderson WN, Pocock S, Smith CR, Leon MB; PARTNER Trial Investigators. Transcatheter aortic-valve replacement for inoperable severe aortic stenosis. N Engl J Med. 2012 May 3;366(18):1696-704. doi: 10.1056/NEJMoa1202277. Epub 2012 Mar 26. Erratum in: N Engl J Med. 2012 Aug 30;367(9):881.</citation>
    <PMID>22443478</PMID>
  </reference>
  <reference>
    <citation>Tousek P, Kocka V, Sulzenko J, Bednar F, Linkova H, Widimsky P. Pharmacodynamic effect of clopidogrel in patients undergoing transcatheter aortic valve implantation. Biomed Res Int. 2013;2013:386074. doi: 10.1155/2013/386074. Epub 2013 Jul 15.</citation>
    <PMID>23956980</PMID>
  </reference>
  <reference>
    <citation>Price MJ, Angiolillo DJ, Teirstein PS, Lillie E, Manoukian SV, Berger PB, Tanguay JF, Cannon CP, Topol EJ. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation. 2011 Sep 6;124(10):1132-7. doi: 10.1161/CIRCULATIONAHA.111.029165. Epub 2011 Aug 29.</citation>
    <PMID>21875913</PMID>
  </reference>
  <reference>
    <citation>Husted S, James S, Becker RC, Horrow J, Katus H, Storey RF, Cannon CP, Heras M, Lopes RD, Morais J, Mahaffey KW, Bach RG, Wojdyla D, Wallentin L; PLATO study group. Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. Circ Cardiovasc Qual Outcomes. 2012 Sep 1;5(5):680-8.</citation>
    <PMID>22991347</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 21, 2014</study_first_submitted>
  <study_first_submitted_qc>August 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2014</study_first_posted>
  <last_update_submitted>June 2, 2017</last_update_submitted>
  <last_update_submitted_qc>June 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital de Meixoeiro</investigator_affiliation>
    <investigator_full_name>Andres Iñiguez Romo, MD, PhD</investigator_full_name>
    <investigator_title>Chief, Cardiology Department, Hospital Alvaro Cunqueiro</investigator_title>
  </responsible_party>
  <keyword>Aortic stenosis</keyword>
  <keyword>TAVI</keyword>
  <keyword>TAVR</keyword>
  <keyword>Transcatheter aortic valve implantation</keyword>
  <keyword>Ticagrelor</keyword>
  <keyword>Antiplatelet reactivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

